Translate Bio Inc $ 13.44 -0.18 (-1.29%)
Warning! GuruFocus has detected 1 Severe warning sign with TBIO. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Translate Bio Inc () from 2018 to Oct 01 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Translate Bio stock (TBIO) PE ratio as of Oct 01 2020 is 0. More Details
Translate Bio PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Translate Bio PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:KNSA NAS:IMAB NAS:CYTK NAS:VCYT NAS:PHAT NAS:BEAM NAS:PTLA NAS:CRTX NAS:NGM NAS:RVNC OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Traded in other countries TBIO.USA
Address 29 Hartwell Avenue, Lexington, MA, USA, 02421
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.